Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)

You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

In the rapidly evolving world of technology, a groundbreaking frontier is emerging that could redefine the very nature of computation: biocomputers. Unlike traditional computers built from silicon-based microchips, biocomputers harness the remarkable processing power of biological systems—often using living cells, DNA molecules, or even entire organisms as computational platforms.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) experienced a notable surge in its stock price as investor enthusiasm for artificial intelligence-driven biotechnology reached new highs. The rally comes amid growing confidence in the company’s platform, which combines advanced machine learning with high-throughput biological experimentation, signaling a potential paradigm shift in the

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and development. Headquartered in Salt Lake City, Utah, the company has positioned itself at the forefront of the intersection between biotechnology and cutting-edge

Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.

Just because it's not a household name doesn't mean it's not a magnificent investment.

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments.

This group of companies reflects most of the industry's past, present, and future.

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading higher and trending. The company on Tuesday announced a reduction in personnel and infrastructure aimed at extending its cash runway.